Navigation Links
Advanced Assay Technologies and Development Methods
Date:1/13/2011

LOS ANGELES, Jan. 13, 2011 /PRNewswire/ -- UBM Canon and IVD Technology are proud to add a new webinar to its webcast series on The Fundamentals of In Vitro Diagnostics.  This one-hour event will focus specifically on Advanced Assay Technologies and Development Methods and will offer an in-depth analysis and discussion from experts in the industry.  

(Logo:  http://photos.prnewswire.com/prnh/20101214/LA16070LOGO)

Various market reports and studies have concluded that the future for immunoassays is a mixed bag. In the clinical laboratory, mature assays will show moderate growth while emerging assays will fuel most of the growth in this IVD segment. However, all immunoassays will have to pass the test of medical research to demonstrate their contributions to improving patient outcomes. In this webinar event, attendees will learn more about how immunoassays, combined with DNA probe studies, will have an important place in post-genomic medicine.

This Webcast will feature presentations by Neal Siegel, PhD, Chief Scientific Officer, Sword Diagnostics; Scott Dylewski, PhD, Senior Scientist, Alverix Inc.; and Nick Gee, PhD, CEO/CSO, Innova Biosciences Ltd. The Webcast concludes with a live Q&A session moderated by Richard Park, Editor-in-Chief of IVD Technology magazine.  For more information on our speakers,

SOURCE UBM Canon
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)
2. CoreLab Partners Launches Advanced Imaging Application
3. Advanced Life Sciences to Explore Strategic Alternatives to Maximize Shareholder Value
4. Advanced Laser Therapy Solutions for Womens Hair Loss
5. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
6. Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease
7. Advanced Radiology Introduces Baltimores First 1.2T High Field Open MRI
8. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
9. Advanced BioHealing Appoints Kevin C. OBoyle as Chief Financial Officer
10. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
11. New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)...  Together with its parent partners and the Community ... initiative of Morris County Prevention is Key (MCPIK), the ... community effort to address the heroin/opiate crisis in ... Volunteer Parent Coaches from the Partnership, ... Denise Mariano , National Council on Alcoholism and Drug ...
(Date:4/27/2015)... 2015 PAML announced today that the ... Axela, Inc. to develop multiplex assays focused on ... of the nation,s leading medical reference laboratories, and ... analysis for clinical diagnostics. Axela,s ... assay development serves as the foundation for novel ...
(Date:4/27/2015)... Calif. , April 27, 2015  Eiger BioPharmaceuticals, ... Phase 2 data of lonafarnib in patients with chronic ... the LOWR HDV program, enrolled at Ankara University Medical ... where HDV is endemic. LOWR HDV ... parallel dose comparison study which randomized subjects to receive ...
Breaking Medicine Technology:Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 3PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
... (NYSE: CFN ), a leading, global medical ... point-of-care verification suite of products across 153 U.S. Department ... centers. (Logo:   http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ... users of barcode medication administration technology and this agreement ...
... NEW YORK, Dec. 6, 2010 Keryx Biopharmaceuticals, ... data presented for the first time at the ... Hematology showing promising clinical activity, safety and tolerability ... leukemia (CLL) and Hodgkin,s lymphoma (HL).  KRX-0401 (perifosine) ...
Cached Medicine Technology:CareFusion to Provide Pyxis® Point-of-Care Products to Veterans Affairs Hospitals Nationwide 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable assisted living community, ... from 10:30 a.m. to noon on May 8. , ... St. in Chicago, serves low-income older adults, including those ... independence. , “Mothers, grandmothers, godmothers and mothers-to-be are invited ... Director of Marketing Elizabeth Clippard. , The menu will ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
(Date:4/27/2015)... How to Implement UDI:, Lessons from Early ... – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI , With ... restraint, there’s plenty of time to get ready for ... deadlines are coming fast for all devicemakers and soon ... even if it seems there’s no rush. It's already ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... mistakenly thought they were taking growth hormone, researchers say ... think they are taking a performance-enhancing drug, their performance ... really take the drug. , So concludes a study ... hormone supplements while the other half took a placebo. ...
... US primary care physicians,Novartis earns the highest sales ... Sanofi-Aventis, according to new,research from TNS Healthcare. Novartis ... consistent ability to build strong physician relationships.,Though Pfizer ... has,greater variability in Europe, while Merck,s European performance ...
... Kimberly-Clark Professional is,donating thousands of health and ... clean up from the extensive damage caused by ... hit very hard by these storms and the,flooding ... Professional, North America. "At Kimberly-Clark,Professional, our mission is ...
... ,Shire Limited (LSE: SHP, Nasdaq: SHPGY), the global ... from a,randomized, long-term safety and tolerability study (study ... primary endpoints,of this study were to assess the ... over 12 months. Data were published in the,July ...
... in cells more readily than a commonly used colorectal ... colorectal tumors, but with fewer side effects, MIT researchers ... a potent anticancer agent, but the newly investigated compound, ... sparing other body tissues from damage. , "This compound, ...
... trauma is an extremely rare condition. There is no ... abdominal trauma. Nonsurgical intervention, especially endoscopic treatment has recently ... case, led by Dr. TH Kim and his colleagues ... 14, 2008 in the World Journal of Gastroenterology. , ...
Cached Medicine News:Health News:Sports Doping's Effect May Be in the Mind 2Health News:Sports Doping's Effect May Be in the Mind 3Health News:Sports Doping's Effect May Be in the Mind 4Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 2Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 3Health News:Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 2Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 3Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 4Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 5Health News:Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal 6Health News:MIT researchers see alternative to common colorectal cancer drug 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
... Reference Series 2000 Pipette is a synonym ... compact and robust design, and superior operating ... to operate the measuring stroke and blow-out ... features:Eppendorf "pipette/tip" system ensures utmost accuracy and ...
500L...
Medicine Products: